Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103622 · ClinicalTrials.gov registry record · Phase 1
Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01103622 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 20 participants.
The verdict
NCT01103622, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether AZD1656 will affect the pharmacokinetics (PK) of digoxin in type 2 diabetes mellitus (T2DM) patients.
Interventions
- DRUG Placebo
- DRUG Digoxin
- DRUG AZD1656
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01103622
The ClinicalTrials.gov registry entry for NCT01103622 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01103622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01103622 about?
NCT01103622 is a clinical study titled "Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients". The purpose of this study is to determine whether AZD1656 will affect the pharmacokinetics (PK) of digoxin in type 2 diabetes mellitus (T2DM) patients.
What is the current status of trial NCT01103622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-06. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01103622?
The interventions under investigation include: Placebo (DRUG), Digoxin (DRUG), AZD1656 (DRUG).
Who is sponsoring clinical trial NCT01103622?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.